References
- Scott KM, Abhinav K, Wijesekera L, Ganesalingam J, Goldstein LH, Janssen A, . The association between ALS and population density: a population based study. Amyotroph Lateral Scler. 2010;11:435–8.
- Zoccolella S, Beghi E, Palagano G, Fraddosio A, Samarelli V, Lamberti P, . Predictors of delay in the diagnosis and clinical trial entry of amyotrophic lateral sclerosis patients: a population based study. J Neurol Sci. 2006;250:45–9.
- Xu Z, Cork LC, Griffin JW, Cleveland DW. Increased expression of neurofilament subunit NF-L produces morphological alterations that resemble the pathology of human motor neuron disease. Cell. 1993;73:23–33.
- Xu Z, Cork LC, Griffin JW, Cleveland DW. Involvement of neurofilaments in motor neuron disease. J Cell Sci Suppl. 1993;17:101–8.
- Brettschneider J, Petzold A, Sussmuth SD, Ludolph AC, Tumani H. Axonal damage markers in cerebrospinal fluid are increased in ALS. Neurology. 2006;66:852–6.
- Reijn TS, Abdo WF, Schelhaas HJ, Verbeek MM. CSF neurofilament protein analysis in the differential diagnosis of ALS. J Neurol. 2009;256:615–9.
- Petzold A, Keir G, Green AJ, Giovannoni G, Thompson EJ. A specific ELISA for measuring neurofilament heavy chain phosphoforms. J Immunol Methods. 2003;278:179–90.
- Petzold A, Shaw G. Comparison of two ELISA methods for measuring levels of the phosphorylated neurofilament heavy chain. J Immunol Methods. 2007;319:34–40.
- Boylan K, Yang C, Crook J, Overstreet K, Heckman M, Wang Y, . Immunoreactivity of the phosphorylated axonal neurofilament H subunit (pNF-H) in blood of ALS model rodents and ALS patients: evaluation of blood pNF-H as a potential ALS biomarker. J Neurochem. 2009;111:1182–91.
- Ganesalingam J, An J, Shaw CE, Shaw G, Lacomis D, Bowser R. Combination of neurofilament heavy chain and complement C3 as CSF biomarkers for ALS. J Neurochem. 2011;117:528–37.
- Corbo M, Hays AP. Peripherin and neurofilament protein coexist in spinal spheroids of motor neuron disease. J Neuropathol Exp Neurol. 1992;51:531–7.
- Parry DA, Steinert PM. Intermediate filaments: molecular architecture, assembly, dynamics and polymorphism. Q Rev Biophys. 1999;32:99–187.
- Nixon RA, Sihag RK. Neurofilament phosphorylation: a new look at regulation and function. Trends Neurosci. 1991; 14:501–6.
- Shea TB, Jung C, Pant HC. Does neurofilament phosphorylation regulate axonal transport?Trends Neurosci. 2003;26:397–400.
- Ganesalingam J, Stahl D, Wijesekera L, Galtrey C, Shaw CE, Leigh PN, . Latent cluster analysis of ALS phenotypes identifies prognostically differing groups. PLoS One. 2009; 4:e7107.
- Wijesekera LC, Mathers S, Talman P, Galtrey C, Parkinson MH, Ganesalingam J, . Natural history and clinical features of the flail arm and flail leg ALS variants. Neurology. 2009; 72:1087–94.
- Otto M, Bowser R, Turner M, Berry J, Brettschneider J, Connor J, . Roadmap and standard operating procedures for biobanking and discovery of neurochemical markers in ALS. Amyotroph Lateral Scler. 2012;13:1–10.